Amundi Sells 3,644 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)

Amundi lowered its position in shares of HUTCHMED (China) Limited (NASDAQ:HCM) by 2.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 170,250 shares of the company’s stock after selling 3,644 shares during the quarter. Amundi’s holdings in HUTCHMED were worth $2,593,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of HCM. State Street Corp raised its holdings in shares of HUTCHMED by 0.9% in the 3rd quarter. State Street Corp now owns 349,524 shares of the company’s stock worth $6,826,000 after purchasing an additional 3,078 shares during the period. Jane Street Group LLC increased its holdings in HUTCHMED by 362.2% during the 3rd quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock worth $1,305,000 after acquiring an additional 49,366 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of HUTCHMED by 99.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company’s stock worth $952,000 after purchasing an additional 24,245 shares during the period. XY Capital Ltd purchased a new stake in shares of HUTCHMED in the 4th quarter valued at about $673,000. Finally, ABC Arbitrage SA purchased a new stake in HUTCHMED in the fourth quarter valued at approximately $500,000. Institutional investors own 8.82% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com lowered HUTCHMED from a “buy” rating to a “hold” rating in a research report on Monday, November 18th.

HUTCHMED Trading Up 2.1 %

HCM stock opened at $15.69 on Monday. HUTCHMED has a fifty-two week low of $12.84 and a fifty-two week high of $21.92. The business’s 50 day moving average price is $14.67 and its two-hundred day moving average price is $16.57. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

HUTCHMED Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.